Form4insider filings, from the source

SEC Form 4 · accession 0001708138-18-000013

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
P Roy Vagelos
Officer — Chairman of the Board · Director
Period of report
Jul 9, 2018
Accepted (ET)
Jul 11, 2018 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJul 9, 2018M153,274$16.80A553,121D
Common StockJul 9, 2018F78,604$370.52D474,517D
Common StockF2Jul 10, 2018S900$364.75D473,617D
Common StockF3Jul 10, 2018S17,221$365.56D456,396D
Common StockF4Jul 10, 2018S24,339$366.49D432,057D
Common StockF5Jul 10, 2018S6,405$367.40D425,652D
Common StockF6Jul 10, 2018S12,211$368.61D413,441D
Common StockF7Jul 10, 2018S13,194$369.41D400,247D
Common StockJul 10, 2018S100$370.17D400,147D
Common StockF8Jul 10, 2018S300$371.29D399,847D
Common StockJul 6, 2018G610$0.00D147,934Iby CLAT
Common Stockholding———2,310IBy 401(k) Plan
Common Stockholding———83,652Iby Spouse as Trustee
Common StockF9holding———1,203Iby trust for grandch

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Non-Qualified Stock Option (right to buy)F10$16.80Jul 9, 2018M153,274D—Dec 17, 2018Common Stock153,2740D

Explanation of responses